Beyond basic research: the contribution of cathepsin B to cancer development, diagnosis and therapy

References

• Cao M, Luo X, Wu K, et al. Targeting lysosomes in human disease: from basic research to clinical applications. Signal Transduct Target Ther. 2021 Nov 8;6(1):379.
   PubMed Web of Science ®Google Scholar
• Eskelinen EL, Tanaka Y, Saftig P. At the acidic edge: emerging functions for lysosomal membrane proteins. Trends Cell Biol. 2003 Mar;13(3):137–145.
   PubMed Web of Science ®Google Scholar
• Soond SM, Kozhevnikova MV, Zamyatnin AA Jr. ‘Patchiness’ and basic cancer research: unravelling the proteases. Cell Cycle. 2019 Aug;18(15):1687–1701.
   PubMed Web of Science ®Google Scholar
• Olson OC, Joyce JA. Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nat Rev Cancer. 2015 Dec;15(12):712–729.
   PubMed Web of Science ®Google Scholar
• Uhlman A, Folkers K, Liston J, et al. Effects of Vacuolar H(+)-ATPase inhibition on activation of cathepsin B and cathepsin L secreted from MDA-MB231 breast cancer cells. Cancer Microenviron. 2017 Dec;10(1–3):49–56.
   PubMed Web of Science ®Google Scholar
• Rozhin J, Sameni M, Ziegler G, et al. Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res. 1994 Dec 15;54(24):6517–6525.
   PubMed Web of Science ®Google Scholar
• Rothberg JM, Bailey KM, Wojtkowiak JW, et al. Acid-mediated tumor proteolysis: contribution of cysteine cathepsins. Neoplasia. 2013 Oct;15(10):1125–1137.
   PubMed Web of Science ®Google Scholar
• Jordans S, Jenko-Kokalj S, Kuhl NM, et al. Monitoring compartment-specific substrate cleavage by cathepsins B, K, L, and S at physiological pH and redox conditions. BMC Biochem. 2009 Sep 22;10:23.
   PubMed Web of Science ®Google Scholar
• Soond SM, Kozhevnikova MV, Frolova AS, et al. Lost or Forgotten: the nuclear cathepsin protein isoforms in cancer. Cancer Lett. 2019 Oct 10;462:43–50.
   PubMed Web of Science ®Google Scholar
• Turk B, Turk D, Turk V. Lysosomal cysteine proteases: more than scavengers. Biochim Biophys Acta. 2000 Mar 7;1477(1–2):98–111.
   PubMed Web of Science ®Google Scholar
• Soond SM, Zamyatnin AA Jr. Helicobacter pylori and gastric cancer: a lysosomal protease perspective. Gastric Cancer. 2022 Mar;25(2):306–324.
   PubMed Web of Science ®Google Scholar
• Soond SM, Kozhevnikova MV, Savvateeva LV, et al. Intrinsically connected: therapeutically targeting the cathepsin proteases and the Bcl-2 family of protein substrates as co-regulators of apoptosis. Int J Mol Sci. 2021 Apr 28;22(9):4669.
   PubMed Web of Science ®Google Scholar
• de Castro MA, Bunt G, Wouters FS. Cathepsin B launches an apoptotic exit effort upon cell death-associated disruption of lysosomes. Cell Death Discov. 2016;2:16012.
   PubMed Web of Science ®Google Scholar
• Turk B, Dolenc I, Turk V, et al. Kinetics of the pH-induced inactivation of human cathepsin L. Biochemistry. 1993 Jan 12;32(1):375–380.
   PubMed Web of Science ®Google Scholar
• Turk B, Bieth JG, Bjork I, et al. Regulation of the activity of lysosomal cysteine proteinases by pH-induced inactivation and/or endogenous protein inhibitors, cystatins. Biol Chem Hoppe-Seyler. 1995 Apr;376(4):225–230.
   PubMed Web of Science ®Google Scholar
• Blum G, von Degenfeld G, Merchant MJ, et al. Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. Nat Chem Biol. 2007 Oct;3(10):668–677.
   PubMed Web of Science ®Google Scholar
• Sanman LE, Bogyo M. Activity-based profiling of proteases. Annu Rev Biochem. 2014;83:249–273.
   PubMed Web of Science ®Google Scholar
• Poreba M, Groborz K, Vizovisek M, et al. Fluorescent probes towards selective cathepsin B detection and visualization in cancer cells and patient samples. Chem Sci. 2019 Sep 28;10(36):8461–8477.
   PubMed Web of Science ®Google Scholar
• Edgington LE, Verdoes M, Bogyo M. Functional imaging of proteases: recent advances in the design and application of substrate-based and activity-based probes. Curr Opin Chem Biol. 2011 Dec;15(6):798–805.
   PubMed Web of Science ®Google Scholar
• Jain M, Bouilloux J, Borrego I, et al. Cathepsin B-cleavable polymeric photosensitizer prodrug for selective photodynamic therapy: in vitro studies. Pharmaceuticals (Basel). 2022 Apr 30;15(5):564.
   Google Scholar
• Chowdhury MA, Moya IA, Bhilocha S, et al. Prodrug-inspired probes selective to cathepsin B over other cysteine cathepsins. J Med Chem. 2014 Jul 24;57(14):6092–6104.
   PubMed Web of Science ®Google Scholar
• Soond SM, Kozhevnikova MV, Townsend PA, et al. Cysteine cathepsin protease inhibition: an update on its diagnostic, prognostic and therapeutic potential in cancer. Pharmaceuticals (Basel). 2019 Jun 11;12(2):87.
   PubMedGoogle Scholar
• Podobnik M, Kuhelj R, Turk V, et al. Crystal structure of the wild-type human procathepsin B at 2.5 A resolution reveals the native active site of a papain-like cysteine protease zymogen. J Mol Biol. 1997 Sep 5;271(5):774–788.
   PubMed Web of Science ®Google Scholar
• Renko M, Pozgan U, Majera D, et al. Stefin A displaces the occluding loop of cathepsin B only by as much as required to bind to the active site cleft. FEBS J. 2010 Oct;277(20):4338–4345.
   PubMed Web of Science ®Google Scholar
• Chan SJ, San Segundo B, McCormick MB, et al. Nucleotide and predicted amino acid sequences of cloned human and mouse preprocathepsin B cDNAs. Proc Natl Acad Sci U S A. 1986 Oct;83(20):7721–7725.
   PubMed Web of Science ®Google Scholar
• Turk V, Stoka V, Vasiljeva O, et al. Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim Biophys Acta. 2012 Jan;1824(1):68–88.
   PubMed Web of Science ®Google Scholar
• Sloane BF, Dunn JR, Honn KV. Lysosomal cathepsin B: correlation with metastatic potential. Science. 1981 Jun 5;212(4499):1151–1153.
   PubMed Web of Science ®Google Scholar
• Ebert MP, Kruger S, Fogeron ML, et al. Overexpression of cathepsin B in gastric cancer identified by proteome analysis. Proteomics. 2005 Apr;5(6):1693–1704.
   PubMed Web of Science ®Google Scholar
• Bengsch F, Buck A, Gunther SC, et al. Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression. Oncogene. 2014 Sep 4;33(36):4474–4484.
   PubMed Web of Science ®Google Scholar
• Fujise N, Nanashim A, Taniguchi Y, et al. Prognostic impact of cathepsin B and matrix metalloproteinase-9 in pulmonary adenocarcinomas by immunohistochemical study. Lung Cancer. 2000 Jan;27(1):19–26.
   PubMed Web of Science ®Google Scholar
• Mort JS, Buttle DJ. Cathepsin B. Int J Biochem Cell Biol. 1997 May;29(5):715–720.
   PubMed Web of Science ®Google Scholar
• Galjart NJ, Gillemans N, Harris A, et al. Expression of cDNA encoding the human “protective protein” associated with lysosomal beta-galactosidase and neuraminidase: homology to yeast proteases. Cell. 1988 Sep 9;54(6):755–764.
   PubMed Web of Science ®Google Scholar
• San Segundo B, Chan SJ, Steiner DF. Differences in cathepsin B mRNA levels in rat tissues suggest specialized functions. FEBS Lett. 1986 Jun 9;201(2):251–256.
   PubMed Web of Science ®Google Scholar
• Ibrahim SA, El-Ghonaimy EA, Hassan H, et al. Hormonal-receptor positive breast cancer: IL-6 augments invasion and lymph node metastasis via stimulating cathepsin B expression. J Adv Res. 2016 Sep;7(5):661–670.
   PubMed Web of Science ®Google Scholar
• Yan S, Berquin IM, Troen BR, et al. Transcription of human cathepsin B is mediated by Sp1 and Ets family factors in glioma. DNA Cell Biol. 2000 Feb;19(2):79–91.
   PubMed Web of Science ®Google Scholar
• Yan S, Jane DT, Dufresne MJ, et al. Transcription of cathepsin B in glioma cells: regulation by an E-box adjacent to the transcription initiation site. Biol Chem. 2003 Oct-Nov;384(10–11):1421–1427.
   PubMed Web of Science ®Google Scholar
• Saffari M, Dinehkabodi OS, Ghaffari SH, et al. Identification of novel p53 target genes by cDNA AFLP in glioblastoma cells. Cancer Lett. 2009 Jan 18;273(2):316–322.
   PubMed Web of Science ®Google Scholar
• Sun T, Jiang D, Zhang L, et al. Expression profile of cathepsins indicates the potential of cathepsins B and D as prognostic factors in breast cancer patients. Oncol Lett. 2016 Jan;11(1):575–583.
   PubMed Web of Science ®Google Scholar
• Soond SM, Savvateeva LV, Makarov VA, et al. Making connections: p53 and the cathepsin proteases as co-regulators of cancer and apoptosis. Cancers (Basel). 2020 Nov 22;12(11):3476.
   Web of Science ®Google Scholar
• Soond SM, Kozhevnikova MV, Townsend PA, et al. Integrative p53, micro-RNA and cathepsin protease co-regulatory expression networks in cancer. Cancers (Basel). 2020 Nov 20;12(11):3454.
   Web of Science ®Google Scholar
• Luan H, Mohapatra B, Bielecki TA, et al. Loss of the nuclear pool of ubiquitin ligase CHIP/STUB1 in breast cancer unleashes the MZF1-Cathepsin Pro-oncogenic Program. Cancer Res. 2018 May 15;78(10):2524–2535.
   PubMed Web of Science ®Google Scholar
• Tripathi R, Fiore LS, Richards DL, et al. Abl and Arg mediate cysteine cathepsin secretion to facilitate melanoma invasion and metastasis. Sci Signal. 2018 Feb 20;11(518):518.
   PubMed Web of Science ®Google Scholar
• Lin YY, Chen ZW, Lin ZP, et al. Tissue levels of Stefin A and Stefin B in hepatocellular carcinoma. Anat Rec (Hoboken). 2016 Apr;299(4):428–438.
   PubMedGoogle Scholar
• Zhang J, He P, Zhong Q, et al. Increasing cystatin C and cathepsin B in serum of colorectal cancer patients. Clin Lab. 2017 Feb 1;63(2):365–371.
   PubMed Web of Science ®Google Scholar
• Tan G, Liu Q, Tang X, et al. Diagnostic values of serum cathepsin B and D in patients with nasopharyngeal carcinoma. BMC Cancer. 2016 Mar 19;16:241.
   PubMed Web of Science ®Google Scholar
• Edgington-Mitchell LE, Bogyo M, Verdoes M. Live cell imaging and profiling of cysteine cathepsin activity using a quenched activity-based probe. Methods Mol Biol. 2017;1491:145–159.
   PubMedGoogle Scholar
• Abe S, Sukoh N, Ogura S, et al. Clinical indicators of malignancy of lung cancer. Hokkaido Igaku Zasshi. 1994 May;69(3):391–395.
   PubMedGoogle Scholar
• Featherston T, Marsh RW, van Schaijik B, et al. Expression and localization of cathepsins B, D, and G in two cancer stem cell subpopulations in moderately differentiated oral tongue squamous cell carcinoma. Front Med (Lausanne). 2017;4:100.
   PubMed Web of Science ®Google Scholar
• Mehrotra S, Wickremesekera SK, Brasch HD, et al. Expression and localization of cathepsins B, D and G in cancer stem cells in liver metastasis from colon adenocarcinoma. Front Surg. 2018;5:40.
   PubMed Web of Science ®Google Scholar
• Ma X, Wang Y, Fan H, et al. Genetic polymorphisms of Cathepsin B are associated with gastric cancer risk and prognosis in a Chinese population. Cancer Biomark. 2021;32(2):189–198.
   PubMed Web of Science ®Google Scholar
• Breznik B, Limbaeck Stokin C, Kos J, et al. Cysteine cathepsins B, X and K expression in peri-arteriolar glioblastoma stem cell niches. J Mol Histol. 2018 Oct;49(5):481–497.
   PubMed Web of Science ®Google Scholar
• Pozgan U, Caglic D, Rozman B, et al. Expression and activity profiling of selected cysteine cathepsins and matrix metalloproteinases in synovial fluids from patients with rheumatoid arthritis and osteoarthritis. Biol Chem. 2010 May;391(5):571–579.
   PubMed Web of Science ®Google Scholar
• Krueger S, Haeckel C, Buehling F, et al. Inhibitory effects of antisense cathepsin B cDNA transfection on invasion and motility in a human osteosarcoma cell line. Cancer Res. 1999 Dec 1;59(23):6010–6014.
   PubMed Web of Science ®Google Scholar
• Withana NP, Blum G, Sameni M, et al. Cathepsin B inhibition limits bone metastasis in breast cancer. Cancer Res. 2012 Mar 1;72(5):1199–1209.
   PubMed Web of Science ®Google Scholar
• Bian B, Mongrain S, Cagnol S, et al. Cathepsin B promotes colorectal tumorigenesis, cell invasion, and metastasis. Mol Carcinog. 2016 May;55(5):671–687.
   PubMed Web of Science ®Google Scholar
• Chan AT, Baba Y, Shima K, et al. Cathepsin B expression and survival in colon cancer: implications for molecular detection of neoplasia. Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2777–2785.
   PubMed Web of Science ®Google Scholar
• Troy AM, Sheahan K, Mulcahy HE, et al. Expression of Cathepsin B and L antigen and activity is associated with early colorectal cancer progression. Eur J Cancer. 2004 Jul;40(10):1610–1616.
   PubMed Web of Science ®Google Scholar
• Hirai K, Yokoyama M, Asano G, et al. Expression of cathepsin B and cystatin C in human colorectal cancer. Hum Pathol. 1999 Jun;30(6):680–686.
   PubMed Web of Science ®Google Scholar
• Yan S, Sloane BF. Molecular regulation of human cathepsin B: implication in pathologies. Biol Chem. 2003 Jun;384(6):845–854.
   PubMed Web of Science ®Google Scholar
• Mehtani S, Gong Q, Panella J, et al. In vivo expression of an alternatively spliced human tumor message that encodes a truncated form of cathepsin B. Subcellular distribution of the truncated enzyme in COS cells. J Biol Chem. 1998 May 22;273(21):13236–13244.
   PubMed Web of Science ®Google Scholar
• Gong Q, Chan SJ, Bajkowski AS, et al. Characterization of the cathepsin B gene and multiple mRNAs in human tissues: evidence for alternative splicing of cathepsin B pre-mRNA. DNA Cell Biol. 1993 May;12(4):299–309.
   PubMed Web of Science ®Google Scholar
• Berquin IM, Cao L, Fong D, et al. Identification of two new exons and multiple transcription start points in the 5’-untranslated region of the human cathepsin-B-encoding gene. Gene. 1995 Jul 4;159(2):143–149.
   PubMed Web of Science ®Google Scholar
• Muntener K, Zwicky R, Csucs G, et al. The alternative use of exons 2 and 3 in cathepsin B mRNA controls enzyme trafficking and triggers nuclear fragmentation in human cells. Histochem Cell Biol. 2003 Feb;119(2):93–101.
   PubMed Web of Science ®Google Scholar
• Hizel C, Ferrara M, Cure H, et al. Evaluation of the 5’ spliced form of human cathepsin B mRNA in colorectal mucosa and tumors. Oncol Rep. 1998 Jan-Feb;5(1):31–34.
   PubMed Web of Science ®Google Scholar
• Lemaire R, Flipo RM, Migaud H, et al. Alternative splicing of the 5’ region of cathepsin B pre-messenger RNA in rheumatoid synovial tissue. Arthritis Rheum. 1997 Aug;40(8):1540–1542.
   PubMedGoogle Scholar
• Aggarwal N, Sloane BF. Cathepsin B: multiple roles in cancer. Proteomics Clin Appl. 2014 Jun;8(5–6):427–437.
   PubMed Web of Science ®Google Scholar
• Mach L, Mort JS, Glossl J. Noncovalent complexes between the lysosomal protease cathepsin B and its propeptide account for stable, extracellular, high molecular mass forms of the enzyme. J Biol Chem. 1994 Apr 29;269(17):13036–13040.
   PubMed Web of Science ®Google Scholar
• Dalet-Fumeron V, Guinec N, Pagano M. In vitro activation of pro-cathepsin B by three serine proteinases: leukocyte elastase, cathepsin G, and the urokinase-type plasminogen activator. FEBS Lett. 1993 Oct 18;332(3):251–254.
   PubMed Web of Science ®Google Scholar
• Gocheva V, Joyce JA. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle. 2007 Jan 1;6(1):60–64.
   PubMed Web of Science ®Google Scholar
• Lin J, McCann AP, Sereesongsaeng N, et al. USP17 is required for peripheral trafficking of lysosomes. EMBO Rep. 2022 Apr 5;23(4):e51932.
   PubMed Web of Science ®Google Scholar
• Zwicky R, Muntener K, Csucs G, et al. Exploring the role of 5’ alternative splicing and of the 3’-untranslated region of cathepsin B mRNA. Biol Chem. 2003 Jul;384(7):1007–1018.
   PubMed Web of Science ®Google Scholar
• Fehrenbacher N, Bastholm L, Kirkegaard-Sorensen T, et al. Sensitization to the lysosomal cell death pathway by oncogene-induced down-regulation of lysosome-associated membrane proteins 1 and 2. Cancer Res. 2008 Aug 15;68(16):6623–6633.
   PubMed Web of Science ®Google Scholar
• Eaton JW, Qian M. Molecular bases of cellular iron toxicity. Free Radic Biol Med. 2002 May 1;32(9):833–840.
   PubMed Web of Science ®Google Scholar
• Kurz T, Terman A, Gustafsson B, et al. Lysosomes and oxidative stress in aging and apoptosis. Biochim Biophys Acta. 2008 Nov;1780(11):1291–1303.
   PubMed Web of Science ®Google Scholar
• Ullio C, Casas J, Brunk UT, et al. Sphingosine mediates TNFalpha-induced lysosomal membrane permeabilization and ensuing programmed cell death in hepatoma cells. J Lipid Res. 2012 Jun;53(6):1134–1143.
   PubMed Web of Science ®Google Scholar
• Mora R, Dokic I, Kees T, et al. Sphingolipid rheostat alterations related to transformation can be exploited for specific induction of lysosomal cell death in murine and human glioma. Glia. 2010 Aug 15;58(11):1364–1383.
   PubMed Web of Science ®Google Scholar
• Taha TA, Kitatani K, Bielawski J, et al. Tumor necrosis factor induces the loss of sphingosine kinase-1 by a cathepsin B-dependent mechanism. J Biol Chem. 2005 Apr 29;280(17):17196–17202.
   PubMed Web of Science ®Google Scholar
• Dielschneider RF, Henson ES, Gibson SB. Lysosomes as oxidative targets for cancer therapy. Oxid Med Cell Longev. 2017;2017:3749157.
   PubMed Web of Science ®Google Scholar
• Ostenfeld MS, Fehrenbacher N, Hoyer-Hansen M, et al. Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Cancer Res. 2005 Oct 1;65(19):8975–8983.
   PubMed Web of Science ®Google Scholar
• Ostenfeld MS, Hoyer-Hansen M, Bastholm L, et al. Anti-cancer agent siramesine is a lysosomotropic detergent that induces cytoprotective autophagosome accumulation. Autophagy. 2008 May;4(4):487–499.
   PubMed Web of Science ®Google Scholar
• Wang Y, Niu H, Hu Z, et al. Targeting the lysosome by an aminomethylated Riccardin D triggers DNA damage through cathepsin B-mediated degradation of BRCA1. J Cell Mol Med. 2019 Mar;23(3):1798–1812.
   PubMed Web of Science ®Google Scholar
• Chung PED, Gendoo DMA, Ghanbari-Azarnier R, et al. Modeling germline mutations in pineoblastoma uncovers lysosome disruption-based therapy. Nat Commun. 2020 Apr 14;11(1):1825.
   PubMed Web of Science ®Google Scholar
• Yuan X, Nie W, He Z, et al. Carbon black nanoparticles induce cell necrosis through lysosomal membrane permeabilization and cause subsequent inflammatory response. Theranostics. 2020;10(10):4589–4605.
   PubMed Web of Science ®Google Scholar
• Bestvater F, Dallner C, Spiess E. The C-terminal subunit of artificially truncated human cathepsin B mediates its nuclear targeting and contributes to cell viability. BMC Cell Biol. 2005 Apr 4;6(1):16.
   PubMedGoogle Scholar
• Meng J, Liu Y, Xie Z, et al. Nucleus distribution of cathepsin B in senescent microglia promotes brain aging through degradation of sirtuins. Neurobiol Aging. 2020;96:255–266.
   PubMed Web of Science ®Google Scholar
• Xu D, Wang J. Downregulation of cathepsin B reduces proliferation and inflammatory response and facilitates differentiation in human HaCaT keratinocytes, ameliorating IL-17A and SAA-induced psoriasis-like lesion. Inflammation. 2021 Oct;44(5):2006–2017.
   PubMed Web of Science ®Google Scholar
• Bach AS, Derocq D, Laurent-Matha V, et al. Nuclear cathepsin D enhances TRPS1 transcriptional repressor function to regulate cell cycle progression and transformation in human breast cancer cells. Oncotarget. 2015 Sep 29;6(29):28084–28103.
   PubMedGoogle Scholar
• Yang Z, Liu Y, Qin L, et al. Cathepsin H-mediated degradation of HDAC4 for matrix metalloproteinase expression in hepatic stellate cells: implications of epigenetic suppression of matrix metalloproteinases in fibrosis through stabilization of class iia histone deacetylases. Am J Pathol. 2017 Apr;187(4):781–797.
   PubMed Web of Science ®Google Scholar
• Goulet B, Baruch A, Moon NS, et al. A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor. Mol Cell. 2004 Apr 23;14(2):207–219.
   PubMed Web of Science ®Google Scholar
• Fei Y, Xiong Y, Shen X, et al. Cathepsin L promotes ionizing radiation-induced U251 glioma cell migration and invasion through regulating the GSK-3beta/CUX1 pathway. Cell Signal. 2018;44:62–71.
   PubMed Web of Science ®Google Scholar
• Goulet B, Sansregret L, Leduy L, et al. Increased expression and activity of nuclear cathepsin L in cancer cells suggests a novel mechanism of cell transformation. Mol Cancer Res. 2007 Sep;5(9):899–907.
   PubMed Web of Science ®Google Scholar
• Soond SM, Savvateeva LV, Makarov VA, et al. Cathepsin S cleaves BAX as a novel and therapeutically important regulatory mechanism for apoptosis. Pharmaceutics. 2021 Mar 5;13(3):339.
   PubMed Web of Science ®Google Scholar
• Tedelind S, Poliakova K, Valeta A, et al. Nuclear cysteine cathepsin variants in thyroid carcinoma cells. Biol Chem. 2010 Aug;391(8):923–935.
   PubMed Web of Science ®Google Scholar
• Muntener K, Zwicky R, Csucs G, et al. Exon skipping of cathepsin B: mitochondrial targeting of a lysosomal peptidase provokes cell death. J Biol Chem. 2004 Sep 24;279(39):41012–41017.
   PubMed Web of Science ®Google Scholar
• Baici A, Muntener K, Willimann A, et al. Regulation of human cathepsin B by alternative mRNA splicing: homeostasis, fatal errors and cell death. Biol Chem. 2006 Aug;387(8):1017–1021.
   PubMed Web of Science ®Google Scholar
• Burton LJ, Henderson V, Liburd L, et al. Snail transcription factor NLS and importin beta1 regulate the subcellular localization of Cathepsin L and Cux1. Biochem Biophys Res Commun. 2017 Sep 9;491(1):59–64.
   PubMed Web of Science ®Google Scholar
• Pouyssegur J, Marchiq I, Parks SK, et al. ‘Warburg effect’ controls tumor growth, bacterial, viral infections and immunity - Genetic deconstruction and therapeutic perspectives. Semin Cancer Biol. 2022 Nov;86(Pt2):334–346.
   Web of Science ®Google Scholar
• Zhelev Z, Aoki I, Lazarova D, et al. A “weird” mitochondrial fatty acid oxidation as a metabolic “secret” of cancer. Oxid Med Cell Longev. 2022;2022:2339584.
   PubMed Web of Science ®Google Scholar
• Gocheva V, Zeng W, Ke D, et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 2006 Mar 1;20(5):543–556.
   PubMed Web of Science ®Google Scholar
• Guinec N, Dalet-Fumeron V, Pagano M. “In vitro” study of basement membrane degradation by the cysteine proteinases, cathepsins B, B-like and L. Digestion of collagen IV, laminin, fibronectin, and release of gelatinase activities from basement membrane fibronectin. Biol Chem Hoppe-Seyler. 1993 Dec;374(12):1135–1146.
   PubMed Web of Science ®Google Scholar
• Mai J, Sameni M, Mikkelsen T, et al. Degradation of extracellular matrix protein tenascin-C by cathepsin B: an interaction involved in the progression of gliomas. Biol Chem. 2002 Sep;383(9):1407–1413.
   PubMed Web of Science ®Google Scholar
• Veillard F, Saidi A, Burden RE, et al. Cysteine cathepsins S and L modulate anti-angiogenic activities of human endostatin. J Biol Chem. 2011 Oct 28;286(43):37158–37167.
   PubMed Web of Science ®Google Scholar
• Joyce JA, Baruch A, Chehade K, et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell. 2004 May;5(5):443–453.
   PubMed Web of Science ®Google Scholar
• Fukuda S, Schmid-Schonbein GW. Regulation of CD18 expression on neutrophils in response to fluid shear stress. Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13152–13157.
   PubMed Web of Science ®Google Scholar
• Nakao S, Zandi S, Sun D, et al. Cathepsin B-mediated CD18 shedding regulates leukocyte recruitment from angiogenic vessels. FASEB J. 2018 Jan;32(1):143–154.
   PubMed Web of Science ®Google Scholar
• Im E, Venkatakrishnan A, Kazlauskas A. Cathepsin B regulates the intrinsic angiogenic threshold of endothelial cells. Mol Biol Cell. 2005 Aug;16(8):3488–3500.
   PubMed Web of Science ®Google Scholar
• Kramer L, Turk D, Turk B. The future of cysteine cathepsins in disease management. Trends Pharmacol Sci. 2017 Oct;38(10):873–898.
   PubMed Web of Science ®Google Scholar
• de Duve C. The lysosome turns fifty. Nat Cell Biol. 2005 Sep;7(9):847–849.
   PubMed Web of Science ®Google Scholar
• Aits S, Jaattela M. Lysosomal cell death at a glance. J Cell Sci. 2013 May 1;126(Pt 9):1905–1912.
   PubMed Web of Science ®Google Scholar
• Cirman T, Oresic K, Mazovec GD, et al. Selective disruption of lysosomes in HeLa cells triggers apoptosis mediated by cleavage of Bid by multiple papain-like lysosomal cathepsins. J Biol Chem. 2004 Jan 30;279(5):3578–3587.
   PubMed Web of Science ®Google Scholar
• Garnett TO, Filippova M, Duerksen-Hughes PJ. Bid is cleaved upstream of caspase-8 activation during TRAIL-mediated apoptosis in human osteosarcoma cells. Apoptosis. 2007 Jul;12(7):1299–1315.
   PubMed Web of Science ®Google Scholar
• Reiners JJ Jr., Caruso JA, Mathieu P, et al. Release of cytochrome c and activation of pro-caspase-9 following lysosomal photodamage involves Bid cleavage. Cell Death Differ. 2002 Sep;9(9):934–944.
   PubMed Web of Science ®Google Scholar
• Conus S, Perozzo R, Reinheckel T, et al. Caspase-8 is activated by cathepsin D initiating neutrophil apoptosis during the resolution of inflammation. J Exp Med. 2008 Mar 17;205(3):685–698.
   PubMed Web of Science ®Google Scholar
• Guicciardi ME, Deussing J, Miyoshi H, et al. Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J Clin Invest. 2000 Nov;106(9):1127–1137.
   PubMed Web of Science ®Google Scholar
• Salvesen GS. A lysosomal protease enters the death scene. J Clin Invest. 2001 Jan;107(1):21–22.
   PubMed Web of Science ®Google Scholar
• Droga-Mazovec G, Bojic L, Petelin A, et al. Cysteine cathepsins trigger caspase-dependent cell death through cleavage of Bid and antiapoptotic Bcl-2 homologues. J Biol Chem. 2008 Jul 4;283(27):19140–19150.
   PubMed Web of Science ®Google Scholar
• Yoon MC, Solania A, Jiang Z, et al. Selective neutral pH inhibitor of cathepsin B designed based on cleavage preferences at cytosolic and lysosomal pH conditions. ACS Chem Biol. 2021 Sep 17;16(9):1628–1643.
   PubMed Web of Science ®Google Scholar
• Turk V, Stoka V, Turk D. Cystatins: biochemical and structural properties, and medical relevance. Front Biosci. 2008 May 1;13:5406–5420.
   PubMed Web of Science ®Google Scholar
• Breznik B, Mitrovic A, TL T, et al. Cystatins in cancer progression: more than just cathepsin inhibitors. Biochimie. 2019;166:233–250.
   PubMed Web of Science ®Google Scholar
• Turk V, Bode W. The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett. 1991 Jul 22;285(2):213–219.
   PubMed Web of Science ®Google Scholar
• Abrahamson M, Barrett AJ, Salvesen G, et al. Isolation of six cysteine proteinase inhibitors from human urine. Their physicochemical and enzyme kinetic properties and concentrations in biological fluids. J Biol Chem. 1986 Aug 25;261(24):11282–11289.
   PubMed Web of Science ®Google Scholar
• Ni J, Fernandez MA, Danielsson L, et al. Cystatin F is a glycosylated human low molecular weight cysteine proteinase inhibitor. J Biol Chem. 1998 Sep 18;273(38):24797–24804.
   PubMed Web of Science ®Google Scholar
• Cygler M, Sivaraman J, Grochulski P, et al. Structure of rat procathepsin B: model for inhibition of cysteine protease activity by the proregion. Structure. 1996 Apr 15;4(4):405–416.
   PubMed Web of Science ®Google Scholar
• Jia Z, Hasnain S, Hirama T, et al. Crystal structures of recombinant rat cathepsin B and a cathepsin B-inhibitor complex. Implications for structure-based inhibitor design. J Biol Chem. 1995 Mar 10;270(10):5527–5533.
   PubMed Web of Science ®Google Scholar
• Musil D, Zucic D, Turk D, et al. The refined 2.15 A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity. EMBO J. 1991 Sep;10(9):2321–2330.
   PubMed Web of Science ®Google Scholar
• Turk D, Podobnik M, Kuhelj R, et al. Crystal structures of human procathepsin B at 3.2 and 3.3 Angstroms resolution reveal an interaction motif between a papain-like cysteine protease and its propeptide. FEBS Lett. 1996 Apr 22;384(3):211–214.
   PubMed Web of Science ®Google Scholar
• Turk D, Podobnik M, Popovic T, et al. Crystal structure of cathepsin B inhibited with CA030 at 2.0-A resolution: a basis for the design of specific epoxysuccinyl inhibitors. Biochemistry. 1995 Apr 11;34(14):4791–4797.
   PubMed Web of Science ®Google Scholar
• Naudin C, Lecaille F, Chowdhury S, et al. The occluding loop of cathepsin B prevents its effective inhibition by human kininogens. J Mol Biol. 2010 Jul 30;400(5):1022–1035.
   PubMed Web of Science ®Google Scholar
• Nagler DK, Storer AC, Portaro FC, et al. Major increase in endopeptidase activity of human cathepsin B upon removal of occluding loop contacts. Biochemistry. 1997 Oct 14;36(41):12608–12615.
   PubMed Web of Science ®Google Scholar
• Illy C, Quraishi O, Wang J, et al. Role of the occluding loop in cathepsin B activity. J Biol Chem. 1997 Jan 10;272(2):1197–1202.
   PubMed Web of Science ®Google Scholar
• Rozman J, Stojan J, Kuhelj R, et al. Autocatalytic processing of recombinant human procathepsin B is a bimolecular process. FEBS Lett. 1999 Oct 15;459(3):358–362.
   PubMed Web of Science ®Google Scholar
• Pungercar JR, Caglic D, Sajid M, et al. Autocatalytic processing of procathepsin B is triggered by proenzyme activity. FEBS J. 2009 Feb;276(3):660–668.
   PubMed Web of Science ®Google Scholar
• Quraishi O, Nagler DK, Fox T, et al. The occluding loop in cathepsin B defines the pH dependence of inhibition by its propeptide. Biochemistry. 1999 Apr 20;38(16):5017–5023.
   PubMed Web of Science ®Google Scholar
• Sloane BF, Rozhin J, Krepela E, et al. The malignant phenotype and cysteine proteinases. Biomed Biochim Acta. 1991;50(4–6):549–554.
   PubMedGoogle Scholar
• Caglic D, Pungercar JR, Pejler G, et al. Glycosaminoglycans facilitate procathepsin B activation through disruption of propeptide-mature enzyme interactions. J Biol Chem. 2007 Nov 9;282(45):33076–33085.
   PubMed Web of Science ®Google Scholar
• Fujimoto T, Tsunedomi R, Matsukuma S, et al. Cathepsin B is highly expressed in pancreatic cancer stem-like cells and is associated with patients’ surgical outcomes. Oncol Lett. 2021 Jan;21(1):30.
   PubMed Web of Science ®Google Scholar
• Mitrovic A, Mirkovic B, Sosic I, et al. Inhibition of endopeptidase and exopeptidase activity of cathepsin B impairs extracellular matrix degradation and tumor invasion. Biol Chem. 2016 Jan 1;397(2):165–174.
   PubMed Web of Science ®Google Scholar
• Jedeszko C, Sloane BF. Cysteine cathepsins in human cancer. Biol Chem. 2004 Nov;385(11):1017–1027.
   PubMed Web of Science ®Google Scholar
• Wang SJ, Chao D, Wei W, et al. CD147 promotes collective invasion through cathepsin B in hepatocellular carcinoma. J Exp Clin Cancer Res. 2020 Jul 29;39(1):145.
   PubMed Web of Science ®Google Scholar
• Ma K, Chen X, Liu W, et al. CTSB is a negative prognostic biomarker and therapeutic target associated with immune cells infiltration and immunosuppression in gliomas. Sci Rep. 2022 Mar 11;12(1):4295.
   PubMed Web of Science ®Google Scholar
• Humphries F, Chang-McDonald B, Patel J, et al. Cathepsins B, D, and G are expressed in metastatic head and neck cutaneous squamous cell carcinoma. Front Oncol. 2021;11:690460.
   PubMed Web of Science ®Google Scholar
• Pandey G, Bakhshi S, Kumar M, et al. Prognostic and therapeutic relevance of cathepsin B in pediatric acute myeloid leukemia. Am J Cancer Res. 2019;9(12):2634–2649.
   PubMed Web of Science ®Google Scholar
• Kozlowski L, Rucinska M, Wojtukiewicz MZ. Metastases of malignant melanoma of unknown primary site: an important diagnostic and therapeutic problem. Pol Merkur Lekarski. 2000 Jul;8(49):486–488.
   PubMedGoogle Scholar
• Yan Y, Zhou K, Wang L, et al. Clinical significance of serum cathepsin B and cystatin C levels and their ratio in the prognosis of patients with esophageal cancer. Onco Targets Ther. 2017;10:1947–1954.
   PubMed Web of Science ®Google Scholar
• Rudzinska-Radecka M, Frolova AS, Balakireva AV, et al. In silico, in vitro, and clinical investigations of cathepsin b and stefin A mRNA expression and a correlation analysis in kidney cancer. Cells. 2022 Apr 25;11(9):1455.
   PubMed Web of Science ®Google Scholar
• Choe Y, Leonetti F, Greenbaum DC, et al. Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities. J Biol Chem. 2006 May 5;281(18):12824–12832.
   PubMed Web of Science ®Google Scholar
• Schmitz J, Gilberg E, Loser R, et al. Cathepsin B: active site mapping with peptidic substrates and inhibitors. Bioorg Med Chem. 2019 Jan 1;27(1):1–15.
   PubMed Web of Science ®Google Scholar
• Li YY, Fang J, Ao GZ. Cathepsin B and L inhibitors: a patent review (2010 - present). Expert Opin Ther Pat. 2017 Jun;27(6):643–656.
   PubMed Web of Science ®Google Scholar
• Hasnain S, Hirama T, Huber CP, et al. Characterization of cathepsin B specificity by site-directed mutagenesis. Importance of Glu245 in the S2-P2 specificity for arginine and its role in transition state stabilization. J Biol Chem. 1993 Jan 5;268(1):235–240.
   PubMed Web of Science ®Google Scholar
• Kato D, Boatright KM, Berger AB, et al. Activity-based probes that target diverse cysteine protease families. Nat Chem Biol. 2005 Jun;1(1):33–38.
   PubMed Web of Science ®Google Scholar
• Lopez-Otin C, Overall CM. Protease degradomics: a new challenge for proteomics. Nat Rev Mol Cell Biol. 2002 Jul;3(7):509–519.
   PubMed Web of Science ®Google Scholar
• Blum G, Weimer RM, Edgington LE, et al. Comparative assessment of substrates and activity based probes as tools for non-invasive optical imaging of cysteine protease activity. PLoS One. 2009 Jul 28;4(7):e6374.
   PubMed Web of Science ®Google Scholar
• Abd-Elrahman I, Kosuge H, Wises Sadan T, et al. Cathepsin activity-based probes and inhibitor for preclinical atherosclerosis imaging and macrophage depletion. PLoS One. 2016;11(8):e0160522.
   PubMed Web of Science ®Google Scholar
• Ben-Aderet L, Merquiol E, Fahham D, et al. Detecting cathepsin activity in human osteoarthritis via activity-based probes. Arthritis Res Ther. 2015 Mar 20;17:69.
   PubMed Web of Science ®Google Scholar
• Bhuiyan AI, Rathod P, Ghoshal S, et al. Clickable, selective, and cell-permeable activity-based probe of human cathepsin B - Minimalistic approach for enhanced selectivity. Bioorg Chem. 2021;117:105463.
   PubMed Web of Science ®Google Scholar
• Oresic Bender K, Ofori L, van der Linden WA, et al. Design of a highly selective quenched activity-based probe and its application in dual color imaging studies of cathepsin S activity localization. J Am Chem Soc. 2015 Apr 15;137(14):4771–4777.
   PubMed Web of Science ®Google Scholar
• Sun N, Wang D, Yao G, et al. pH-dependent and cathepsin B activable CaCO3 nanoprobe for targeted in vivo tumor imaging. Int J Nanomedicine. 2019;14:4309–4317.
   PubMed Web of Science ®Google Scholar
• Wang S, Vigliarolo BG, Chowdhury MA, et al. Design and synthesis of fluorogenic substrate-based probes for detecting Cathepsin B activity. Bioorg Chem. 2019;92:103194.
   PubMed Web of Science ®Google Scholar
• Shen Y, Wu T, Wang Y, et al. Nucleolin-targeted ratiometric fluorescent carbon dots with a remarkably large emission wavelength shift for precise imaging of cathepsin b in living cancer cells. Anal Chem. 2021 Mar 2;93(8):4042–4050.
   PubMed Web of Science ®Google Scholar
• Tam LKB, Yu L, Wong RCH, et al. Dual cathepsin b and glutathione-activated dimeric and trimeric phthalocyanine-based photodynamic molecular beacons for targeted photodynamic therapy. J Med Chem. 2021 Dec 9;64(23):17455–17467.
   PubMed Web of Science ®Google Scholar
• Wang Y, Jiang L, Zhang Y, et al. Fibronectin-targeting and cathepsin B-activatable theranostic nanoprobe for MR/fluorescence imaging and enhanced photodynamic therapy for triple negative breast cancer. ACS Appl Mater Interfaces. 2020 Jul 29;12(30):33564–33574.
   PubMed Web of Science ®Google Scholar
• Tan P, Cai H, Wei Q, et al. Enhanced chemo-photodynamic therapy of an enzyme-responsive prodrug in bladder cancer patient-derived xenograft models. Biomaterials. 2021;277:121061.
   PubMed Web of Science ®Google Scholar
• Kramer L, Renko M, Zavrsnik J, et al. Non-invasive in vivo imaging of tumor-associated cathepsin B by a highly selective inhibitory DARPin. Theranostics. 2017;7(11):2806–2821.
   PubMed Web of Science ®Google Scholar
• Schenker P, Alfarano P, Kolb P, et al. A double-headed cathepsin B inhibitor devoid of warhead. Protein Sci. 2008 Dec;17(12):2145–2155.
   PubMed Web of Science ®Google Scholar
• Murata M, Miyashita S, Yokoo C, et al. Novel epoxysuccinyl peptides. Selective inhibitors of cathepsin B, in vitro. FEBS Lett. 1991 Mar 25;280(2):307–310.
   PubMed Web of Science ®Google Scholar
• Raghav N, Singh M. SAR studies of some acetophenone phenylhydrazone based pyrazole derivatives as anticathepsin agents. Bioorg Chem. 2017 Dec;75:38–49.
   PubMed Web of Science ®Google Scholar
• Kim J, Shim MK, Cho YJ, et al. The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis. Biomaterials. 2021;279:121189.
   PubMed Web of Science ®Google Scholar
• Herceg V, Bouilloux J, Janikowska K, et al. Cathepsin B-cleavable cyclopeptidic chemotherapeutic prodrugs. Molecules. 2020 Sep 18;25(18):4285.
   PubMed Web of Science ®Google Scholar
• Zhang HJ, Zhao X, Chen LJ, et al. pH-driven targeting nanoprobe with dual-responsive drug release for persistent luminescence imaging and chemotherapy of tumor. Anal Chem. 2020 Jan 7;92(1):1179–1188.
   PubMed Web of Science ®Google Scholar
• Shim MK, Park J, Yoon HY, et al. Carrier-free nanoparticles of cathepsin B-cleavable peptide-conjugated doxorubicin prodrug for cancer targeting therapy. J Control Release. 2018 Dec 11;294:376–389.
   PubMed Web of Science ®Google Scholar
• Zhi X, Jiang Y, Xie L, et al. Gold nanorods functionalized with cathepsin B targeting peptide and doxorubicin for combinatorial therapy against multidrug resistance. ACS Appl Bio Mater. 2019 Dec 16;2(12):5697–5706.
   PubMedGoogle Scholar
• Ben-Nun Y, Fichman G, Adler-Abramovich L, et al. Cathepsin nanofiber substrates as potential agents for targeted drug delivery. J Control Release. 2017 Jul 10;257:60–67.
   PubMed Web of Science ®Google Scholar
• Lee S, Song SJ, Lee J, et al. Cathepsin B-responsive liposomes for controlled anticancer drug delivery in hep G2 cells. Pharmaceutics. 2020 Sep 14;12(9):876.
   Web of Science ®Google Scholar
• Cho H, Shim MK, Yang S, et al. Cathepsin B-overexpressed tumor cell activatable albumin-binding doxorubicin prodrug for cancer-targeted therapy. Pharmaceutics. 2021 Dec 29;14(1):83.
   PubMed Web of Science ®Google Scholar
• Schnorenberg MR, Bellairs JA, Samaeekia R, et al. Activating the intrinsic pathway of apoptosis using BIM BH3 peptides delivered by peptide amphiphiles with endosomal release. Materials (Basel). 2019 Aug 12;12(16):2567.
   PubMed Web of Science ®Google Scholar
• Ehrsam D, Porta F, Hussner J, et al. PDMS-PMOXA-nanoparticles featuring a cathepsin b-triggered release mechanism. Materials (Basel). 2019 Sep 3;12(17):2836.
   PubMed Web of Science ®Google Scholar
• Luo Y, Sun X, Huang L, et al. Artemisinin-based smart nanomedicines with self-supply of ferrous ion to enhance oxidative stress for specific and efficient cancer treatment. ACS Appl Mater Interfaces. 2019 Aug 21;11(33):29490–29497.
   PubMed Web of Science ®Google Scholar
• Jin X, Zhang J, Jin X, et al. Folate receptor targeting and cathepsin b-sensitive drug delivery system for selective cancer cell death and imaging. ACS Med Chem Lett. 2020 Aug 13;11(8):1514–1520.
   PubMed Web of Science ®Google Scholar
• Saito K, Iioka H, Kojima C, et al. Peptide-based tumor inhibitor encoding mitochondrial p14(ARF) is highly efficacious to diverse tumors. Cancer Sci. 2016 Sep;107(9):1290–1301.
   PubMed Web of Science ®Google Scholar
• Shim MK, Moon Y, Yang S, et al. Cancer-specific drug-drug nanoparticles of pro-apoptotic and cathepsin B-cleavable peptide-conjugated doxorubicin for drug-resistant cancer therapy. Biomaterials. 2020;261:120347.
   PubMed Web of Science ®Google Scholar
• Narayanan P, Anitha AK, Ajayakumar N, et al. Poly-lysine dendritic nanocarrier to target epidermal growth factor receptor overexpressed breast cancer for methotrexate delivery. Materials (Basel). 2022 Jan 21;15(3):800.
   Web of Science ®Google Scholar
• Wang W, Zhang X, Li Z, et al. Dendronized hyaluronic acid-docetaxel conjugate as a stimuli-responsive nano-agent for breast cancer therapy. Carbohydr Polym. 2021 Sep 1;267:118160.
   PubMed Web of Science ®Google Scholar
• Kim J, Shim MK, Yang S, et al. Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance. J Control Release. 2021 Feb 10;330:920–932.
   PubMed Web of Science ®Google Scholar
• Cheng X, Li J, Tanaka K, et al. MORAb-202, an antibody-drug conjugate utilizing humanized anti-human FRalpha farletuzumab and the microtubule-targeting agent eribulin, has potent antitumor activity. Mol Cancer Ther. 2018 Dec;17(12):2665–2675.
   PubMed Web of Science ®Google Scholar
• Furuuchi K, Rybinski K, Fulmer J, et al. Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models. Cancer Sci. 2021 Jun;112(6):2467–2480.
   PubMed Web of Science ®Google Scholar
• Yang S, Shim MK, Kim WJ, et al. Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity. Biomaterials. 2021;272:120791.
   PubMed Web of Science ®Google Scholar
• Moon Y, Shim MK, Choi J, et al. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death. Theranostics. 2022;12(5):1999–2014.
   PubMed Web of Science ®Google Scholar
• Korkmaz B, Lamort AS, Domain R, et al. Cathepsin C inhibition as a potential treatment strategy in cancer. Biochem Pharmacol. 2021;194:114803.
   PubMed Web of Science ®Google Scholar
• Vizovisek M, Vidak E, Javorsek U, et al. Cysteine cathepsins as therapeutic targets in inflammatory diseases. Expert Opin Ther Targets. 2020 Jun;24(6):573–588.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Fujiwara Y, Yonemori K, et al. First-in-human phase 1 study of MORAb-202, an antibody-drug conjugate comprising farletuzumab linked to eribulin mesylate, in patients with folate receptor-alpha-positive advanced solid tumors. Clin Cancer Res. 2021 Jul 15;27(14):3905–3915.
   PubMed Web of Science ®Google Scholar